MorphoSys (ETR:MOR – Get Rating) has been assigned a €34.00 ($35.05) target price by equities researchers at JPMorgan Chase & Co. in a research report issued on Thursday, Borsen Zeitung reports. JPMorgan Chase & Co.‘s price target would suggest a potential upside of 51.58% from the stock’s current price.
Several other equities research analysts also recently issued reports on the company. Deutsche Bank Aktiengesellschaft set a €30.00 ($30.93) price objective on MorphoSys in a report on Wednesday, July 27th. Berenberg Bank set a €65.00 ($67.01) price objective on MorphoSys in a report on Thursday. Finally, The Goldman Sachs Group set a €24.00 ($24.74) price objective on MorphoSys in a report on Friday, June 10th.
MorphoSys Price Performance
MOR stock opened at €22.43 ($23.12) on Thursday. The company has a quick ratio of 2.71, a current ratio of 2.98 and a debt-to-equity ratio of 231.51. MorphoSys has a 52-week low of €16.45 ($16.96) and a 52-week high of €51.60 ($53.20). The stock’s 50 day moving average is €20.55 and its two-hundred day moving average is €22.58. The company has a market capitalization of $765.96 million and a PE ratio of -1.25.
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma.
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.